Key facts
- This page summarizes Anastasios Gianakakos's Form 3 filing for LianBio (LIANY).
- 0 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 29 Oct 2021, 18:18.
Anastasios Gianakakos - 29 Oct 2021 Form 3 Insider Report for LianBio (LIANY)
- Reporting relationship
- Director
- Issuer ticker
- LIANY
- Reported as of
- 29 Oct 2021
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 29 Oct 2021, 18:18:13 UTC
- Next SEC filing
- 03 Jan 2022
- Source filing
- View source filing
- Reporting owner signature
- By /s/ Angela Chen, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Anastasios Gianakakos filed Form 3 for LianBio (LIANY) on 29 Oct 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
LIAN
holding
Ordinary Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 309,623
- Date
- 29 Oct 2021
- Ownership
- By Trust
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
LIAN
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 29 Oct 2021
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 146,195
- Exercise price
- $6.49
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
25% of the shares underlying the option shall vest and become exercisable on the first anniversary of the commencement date, December 17, 2021; the remainder shall vest and become exercisable in 3 equal annual installments such that the option shall be fully vested on December 17, 2024, subject to the Reporting Person providing continuous service to the Issuer on each such date.
SEC remarks
Exhibit List: Exhibit 24 - Power of Attorney